Clarifying indication priorities for a multi-indication asset.

A specialty pharma team was assessing where to focus development and commercial effort for an asset with potential across several indications. The internal debate had become difficult because different teams were working from different assumptions about market size, competitive intensity, access constraints, evidence requirements and launch timing. The result was plenty of analysis, but no clear view on which opportunities genuinely deserved priority.

DSX supported the team with a structured portfolio strategy review. The work compared the indications through a commercial lens, looking at treatable population, differentiation, pipeline evolution, pricing and access, time to market, and launch sequencing across key geographies. Scenario work was used to test how the ranking changed if competitor timing moved, access proved slower than expected, or evidence requirements created delays. This reflects DSX's portfolio strategy offer around indication prioritisation, competitive positioning, launch sequencing, portfolio risk mapping and scenario planning.

The outcome was not just a ranked list of indications, but a clearer view of where the opportunity was strongest, where the assumptions were weakest, and how sequencing choices would affect portfolio value over time. Leadership discussions became more focused, and the team had a stronger basis for deciding where to invest first.